Non-Melanoma Skin Cancers

An ACMS poster session delves into the role artificial intelligence can play in the treatment of basal cell carcinoma.

A poster session and ACMS keynote speaker Anant Madabhushi, MS, PhD, both delve into the use of AI in Mohs surgery.

Bar will share insight on foldover interpolated flaps for full thickness of nasal defects.

From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.

The task force defined screening as a visual skin exam by a primary care clinician for this recommendation.

Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.

With the advent of immunotherapy, the 1-year survival rate for patients with metastatic melanoma has increased from 25% to 50%.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

The commander-in-chief’s cancerous tissue was successfully removed last month.

Transplant patients are at a higher risk of nonmelanoma carcinomas due to immunosuppressive therapies.

In this week’s Pointers with Dr Portela, the 208SkinDoc discusses basal cell carcinoma and Mohs surgery related to Jill Biden's most recent skin cancer diagnosis.

Merkel cell carcinoma is a rare but highly aggressive type of nonmelanoma skin cancer and Merkel cell polyomavirus is thought to play a major role in its etiology.

This review will explore various leukemia-related cutaneous findings and discuss the diagnosis and management of these conditions.

Darrell S. Rigel shares current updates in skin cancer treatments and incidences across the US at Winter Clinical Hawaii.

New clues about the immune system response to MCC may be able to help guide future treatment strategies.

In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.

Although Merkel cell carcinoma can develop undetected or at a metastasized site, it usually first appears as a painless lump or nodule on an area of the skin that has been exposed to the sun.

Merkel cell carcinoma is a rare, aggressive cutaneous malignancy that originates due to the uncontrollable proliferation of Merkel cells.

Eccrine porocarcinoma is a rare, aggressive tumor that originates from the intraepidermal ducts of eccrine glands.

Findings from a retrospective cohort study found that immune checkpoint inhibitors induced promising responses in the first- and second-line treatment of head and neck squamous cell carcinoma.

Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.

The 40-gene expression profile (40-GEP) test can focus treatment options and optimize patient outcomes, according to a poster presentation at the 2022 Fall Clinical Dermatology Conference.

At the 2022 Fall Clinical Dermatology Conference in Las Vegas, a look at the latest technology for treating basal cell carcinoma and nonmelanoma skin cancer.

Immune checkpoint inhibitor therapy does not appear to increase complication rates in patients undergoing dermatologic procedures, according to a video oral abstract presentation at the 2022 ASDS Annual Meeting.

Sherrif Ibrahim, MD, PhD, provides key pearls from his co-directed session at the 2022 Annual ASDS Meeting, “Defining ‘High-Risk’ for Squamous Cell Carcinoma: Implications for Treatment Paradigms.”